Alberto Chiarugi mostly deals with Poly ADP ribose polymerase, Pharmacology, Biochemistry, Cell biology and Programmed cell death. The various areas that Alberto Chiarugi examines in his Poly ADP ribose polymerase study include Apoptosis, DNA repair and NAD+ kinase. His NAD+ kinase research includes themes of Glycolysis, Molecular biology, Flow cytometry, Membrane potential and Mitochondrion.
Alberto Chiarugi has included themes like Nitric oxide synthase, Meninges, Kynurenine and Olaparib in his Pharmacology study. His work deals with themes such as Transcription factor, Neurodegeneration and Neuroscience, Neuron, which intersect with Cell biology. He combines subjects such as Cytochrome, Cell nucleus and Ischemia with his study of Programmed cell death.
Alberto Chiarugi mainly focuses on Poly ADP ribose polymerase, Pharmacology, Neuroprotection, Biochemistry and Molecular biology. His Poly ADP ribose polymerase research is multidisciplinary, incorporating perspectives in Programmed cell death, NAD+ kinase and Cell biology. His Cell biology study incorporates themes from Apoptosis, Transcription factor, Transcriptional regulation and Neuroscience.
His work investigates the relationship between Pharmacology and topics such as Kynurenine that intersect with problems in Indoleamine 2,3-dioxygenase and Enzyme inhibitor. His Neuroprotection research integrates issues from Neurodegeneration, Hippocampal formation, Brain ischemia, Ischemia and Brain damage. As part of the same scientific family, Alberto Chiarugi usually focuses on Molecular biology, concentrating on Protein kinase B and intersecting with Neuron.
His scientific interests lie mostly in Pharmacology, Migraine, Dexpramipexole, NOD mice and Experimental autoimmune encephalomyelitis. In general Pharmacology study, his work on Neuropathic pain often relates to the realm of Chloramphenicol, thereby connecting several areas of interest. His NOD mice research includes elements of Myelin oligodendrocyte glycoprotein, Lymphocyte proliferation, Immunology and Entinostat.
Alberto Chiarugi works mostly in the field of Immunology, limiting it down to topics relating to Myelin and, in certain cases, Dexamethasone, Neurodegeneration and Immune system. Alberto Chiarugi has researched Experimental autoimmune encephalomyelitis in several fields, including Cancer research, Panobinostat and Givinostat. His Neuroprotection research is multidisciplinary, incorporating elements of Hippocampal formation, Mitochondrion and Pathogenesis.
Alberto Chiarugi focuses on Pharmacology, Pharmacokinetics, Neuropathic pain, Nociception and Tolerability. His research in Pharmacology intersects with topics in Sumatriptan, Disease cluster, Symptomatic treatment, Brain uptake and Migraine. His Pharmacokinetics study combines topics in areas such as Chromatography, Polyethylene glycol, Bioavailability and In vivo.
His Neuropathic pain research integrates issues from Nociceptor and Dorsal root ganglion.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The NAD metabolome — a key determinant of cancer cell biology
Alberto Chiarugi;Christian Dölle;Roberta Felici;Mathias Ziegler.
Nature Reviews Cancer (2012)
Poly(ADP-ribose) polymerase: killer or conspirator? The ‘suicide hypothesis’ revisited
Trends in Pharmacological Sciences (2002)
Delayed inflammation in rat meninges: implications for migraine pathophysiology.
Uwe Reuter;Hayrunnisa Bolay;Inger Jansen-Olesen;Alberto Chiarugi.
The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension
Marco Porcu;Alberto Chiarugi.
Trends in Pharmacological Sciences (2005)
BID mediates neuronal cell death after oxygen/ glucose deprivation and focal cerebral ischemia
Nikolaus Plesnila;Sandra Zinkel;Dean A. Le;Sepideh Amin-Hanjani.
Proceedings of the National Academy of Sciences of the United States of America (2001)
Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders.
Alberto Chiarugi;Michael A. Moskowitz.
Journal of Neurochemistry (2003)
Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.
Giuseppe Faraco;Tristano Pancani;Laura Formentini;Paolo Mascagni.
Molecular Pharmacology (2006)
High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo
G. Faraco;S. Fossati;M. E. Bianchi;M. Patrone.
Journal of Neurochemistry (2007)
Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities
R. Carpenedo;A. Chiarugi;P. Russi;G. Lombardi.
Nuclear factor-kappaB as a molecular target for migraine therapy.
U Reuter;A Chiarugi;H Bolay;MA Moskowitz.
Annals of Neurology (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: